Polymeric gene delivery for diabetic treatment

Diabetes and Metabolism Journal

Volumn 35, Issue 4, 2011, Pages 317-326

  Kim, Sung Wan ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Hanyang University   (South Korea)

Author keywords

Fassirna; Gad mrna; Il 10 plasmid dna; Sp ex4

Indexed keywords

EID: 84864670286     PISSN: 22336079     EISSN: 22336087     Source Type: Journal    
DOI: 10.4093/dmj.2011.35.4.317     Document Type: Review

References (35)

1. Rolland AP. From genes to gene medicines: recent advances in nonviral gene delivery. Crit Rev Ther Drug Carrier Syst 1998; 15:143-98.
2. Peel D. Virus vectors and gene therapy: problems, promises and prospects. MBChB Special Study Module Project Report. Leicester: Department of Microbiology and Immunology, University of Leicester; 1998.
3. Anchordoquy TJ, Koe GS. Physical stability of nonviral plasmid-based therapeutics. J Pharm Sci 2000;89:289-96.
4. Garnett MC. Gene-delivery systems using cationic polymers. Crit Rev Ther Drug Carrier Syst 1999;16:147-207.
5. Huang L, Hung M, Wagner E. Nonviral vectors for gene therapy. San Diego: Academic Press; 1999. p3-22.
6. Kawabata K, Takakura Y, Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm Res 1995;12:825-30.
7. American Diabetes Association. Available from: http://www.diabetes.org (cited 2011 Jan 12).
8. Anderson R, Jones P. What's new in type 2 diabetes? Liverpool: National Prescribing Centre; 2000.
9. Lorenzana GG, Hsia SH. The pharmacotherapy of type 2 diabetes to achieve tight glycemic control. Home Health Care Consult 2002;9:10-6.
10. Malaisse WJ, Lebrun P. Mechanisms of sulfonylurea-induced insulin release. Diabetes Care 1990;13 Suppl 3:9-17.
11. Davies MJ. Insulin secretagogues. Curr Med Res Opin 2002:18 (1 Suppl 1):22-30.
12. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001;414:821-7.
13. Koh JJ, Ko KS, Lee M, Han S, Park JS, Kim SW. Degradable polymeric carrier for the delivery of IL-10 plasmid DNA to prevent autoimmune insulitis of NOD mice. Gene Ther 2000; 7:2099-104.
14. Lee M, Han S, Ko KS, Kim SW. Cell type specific and glucose responsive expression of interleukin-4 by using insulin promoter and water soluble lipopolymer. J Control Release 2001; 75:421-9.
15. Ko KS, Lee M, Koh JJ, Kim SW. Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic mice. Mol Ther 2001;4:313-6.
16. Lee M, Han SO, Ko KS, Koh JJ, Park JS, Yoon JW, Kim SW. Repression of GAD autoantigen expression in pancreas beta-Cells by delivery of antisense plasmid/PEG-g-PLL complex. Mol Ther 2001;4:339-46.
17. Jeong JH, Lee M, Kim WJ, Yockman JW, Park TG, Kim YH, Kim SW. Anti-GAD antibody targeted non-viral gene delivery to islet beta cells. J Control Release 2005;107:562-70.
18. La Barre J, Still EU. Studies on physiology of secretin. III. Further studies on the effects of secretin on blood sugar. Am J Physiol 1930;91:649-53.
19. Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia 1985;28:565-73.
20. Creutzfeldt W. The incretin concept today. Diabetologia 1979; 16:75-85.
21. Beck B. Gastric inhibitory polypeptide: a gut hormone with anabolic functions. J Mol Endocrinol 1989;2:169-74.
22. Lund PK, Goodman RH, Montminy MR, Dee PC, Habener JF. Anglerfish islet pre-roglucagon II. Nucleotide and corresponding amino acid sequence of the cDNA. J Biol Chem 1983;258: 3280-4.
23. Lopez LC, Frazier ML, Su CJ, Kumar A, Saunders GF. Mammalian pancreatic preproglucagon contains three glucagon-related peptides. Proc Natl Acad Sci U S A 1983;80:5485-9.
24. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002;51 Suppl 3:S434-42.
25. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF. Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 1992;15:270-6.
26. Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999;42:856-64.
27. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000;141:4600-5.
28. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80:952-7.
29. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001;142:521-7.
30. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-4.
31. Pridal L, Agerbaek H, Christensen LN, Thomsen K, Kirk O. Absorption of glucagons-like peptide-1 can be protracted by zinc or protamine. Int J Pharm 1996;136:53-9.
32. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47:1663-70.
33. Oh S, Lee M, Ko KS, Choi S, Kim SW. GLP-1 gene delivery for the treatment of type 2 diabetes. Mol Ther 2003;7:478-83.
34. Choi S, Oh S, Lee M, Kim SW. Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes. Mol Ther 2005;12:885-91.
35. Jeong JH, Kim SH, Lee M, Kim WJ, Park TG, Ko KS, Kim SW. Non-viral systemic delivery of Fas siRNA suppresses cyclophosphamide-induced diabetes in NOD mice. J Control Release 2010;143:88-94.